|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
Role of peroxisome proliferator-activated receptor-gamma activation on visfatin, advanced glycation end products, and renal oxidative stress in obesity-induced type 2 diabetes mellitus.
|
29441829 |
2018 |
|
Obesity
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Soya protein β-conglycinin ameliorates fatty liver and obesity in diet-induced obese mice through the down-regulation of PPARγ.
|
29770757 |
2018 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
We developed and tested a novel dual modulator, RB394, which acts as a soluble epoxide hydrolase (sEH) inhibitor and a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist in rat models of the metabolic syndrome-the obese spontaneously hypertensive (SHROB) rat and the obese diabetic Zucker fatty/spontaneously hypertensive heart failure F1 hybrid (ZSF1) rat.
|
30032428 |
2018 |
|
Obesity
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Hypocaloric diet reduces UCP3 expression in individuals with obesity and the UCP3, PLIN1 and PPARG2 expression correlate positively with carbohydrate oxidation and negatively with lipid oxidation.
|
28651828 |
2018 |
|
Obesity
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Indeed, altered PPARγ transcriptional activity contributes to metabolic syndromes (obesity and hyperglycemia associated with type 2 diabetes mellitus), stroke and neurodegenerative diseases.
|
29964054 |
2018 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
Rosiglitazone (ROSI), a member of thiazolidinediones (TZDs) which act as high-affinity agonists of the nuclear receptor peroxisome-proliferator-activated receptor-γ (PPARγ), is clinically used as an antidiabetic drug which could attenuate the insulin resistance associated with obesity, hypertension, and impaired glucose tolerance in humans.
|
30278161 |
2018 |
|
Obesity
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Tumor necrosis factor-α (TNF-α), peroxisome proliferator-activated receptor-γ (PPARγ), and insulin receptor substrate-1 (IRS-1) are associated with obesity, insulin resistance, and inflammation.
|
29256014 |
2018 |
|
Obesity
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
In a Mexican population characterized by high-fat consumption, we hypothesized that the Pro12Ala PPARγ genotype is related to obesity and this relationship is modulated by intake of saturated fatty acids (SFAs) and trans-fatty acids (TFAs).
|
30122193 |
2018 |
|
Obesity
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
The obesity suppression was associated with reductions in expression of adipogenic proteins, such as C/EBPα and PPARγ, increases in expression of lipolytic enzymes, such as adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL), in WAT of HFD-fed mice.
|
30463291 |
2018 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
This review suggests that Hcy contributes to pyroptosis, changes gut microbiome, and alters PPARγ-dependent mechanism(s) via Zfp407-mediated upregulated adipogenesis and misbalanced fatty acid metabolism, which can predispose to obesity and, consequently, obesity-related metabolic disorders.
|
29890083 |
2018 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
Caffeic Acid Phenethyl Ester Improves Metabolic Syndrome by Activating PPAR-γ and Inducing Adipose Tissue Remodeling in Diet-Induced Obese Mice.
|
29508519 |
2018 |
|
Obesity
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to evaluate ANGPTL4 plasma levels and PPARγ gene expression in peripheral blood mononuclear cells (PBMCs) of children and adolescents with obesity and their association with metabolic parameters.
|
28733963 |
2018 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
Ablation of PPARγ in subcutaneous fat exacerbates age-associated obesity and metabolic decline.
|
29383825 |
2018 |
|
Obesity
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We tested whether a targeted reduction in hepatic peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), which has been shown to occur with obesity, had a negative impact on the metabolic effects of FGF21.
|
29215172 |
2018 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the association of selected single nucleotide polymorphisms (SNPs) of cluster of differentiation 36 (CD36) and peroxisome proliferator-activated receptor γ (PPARγ) with VPA-induced weight gain and obesity in epileptic patients.
|
29984389 |
2018 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
Peroxisome Proliferator-Activated Receptor Gamma in Obesity and Colorectal Cancer: the Role of Epigenetics.
|
28878369 |
2017 |
|
Obesity
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Phtalates are thought to contribute to obesity through their binding and activation of PPARγ receptor that in turn results in the upregulation of adipocyte production.
|
27358237 |
2017 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
Our results suggest that a novel MG derivative, CBMG may have beneficial applications in the control of obesity through the suppression of PPARγ-induced adipocyte differentiation and lipid accumulation.
|
28625492 |
2017 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
Furthermore, the transcript and protein levels of transcriptional coactivator peroxisome proliferator-activated receptor γ (PPARγ) coactivator 1α (PGC-1α) and estrogen-related receptor-α (ERRα) in DIO-R mice were significantly up-regulated compared with the DIO mice.
|
28444662 |
2017 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
In summary, our results show that neuronal PPARγ is required for optimal female fertility but is also involved in the adverse effects of diet-induced obesity by creating leptin resistance potentially through induction of the repressor Socs3.
|
27841948 |
2017 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
Although the mechanisms are still not completely understood, prebiotics, probiotics, polyphenols, peroxisome proliferator-activated receptor-γ agonists (such as rosiglitazone) and exercise have been shown to reverse HFD-induced intestinal phenotype and to attenuate the severity of obesity and its associated metabolic complications.
|
28571979 |
2017 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
It is well-documented that CL316,243 (a β3 agonist) or rosiglitazone (a PPARγ agonist) can induce white adipocyte populations to brown-like adipocytes, thus increasing energy consumption and combating obesity.
|
28481288 |
2017 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
DBZ is a putative PPARγ agonist that prevents HFD-induced obesity-related metabolic syndrome and reverse gut dysbiosis.
|
28736228 |
2017 |
|
Obesity
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Interaction between peroxisome proliferator-activated receptor gamma polymorphism and obesity on type 2 diabetes in a Chinese Han population.
|
28123453 |
2017 |
|
Obesity
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Down-regulation of vascular PPAR-γ contributes to endothelial dysfunction in high-fat diet-induced obese mice exposed to chronic intermittent hypoxia.
|
28822761 |
2017 |